» Articles » PMID: 24811546

Sevelamer Carbonate: a Review in Hyperphosphataemia in Adults with Chronic Kidney Disease

Overview
Journal Drugs
Specialty Pharmacology
Date 2014 May 10
PMID 24811546
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Sevelamer carbonate (Renvela(®)), a buffered form of sevelamer hydrochloride (Renagel(®)), is an orally administered non-absorbed phosphate-binding anion exchange resin used in the treatment of hyperphosphataemia in chronic kidney disease (CKD). In the EU, sevelamer carbonate is approved in adult CKD patients who require dialysis and in those who do not require dialysis with serum phosphate levels ≥ 1.78 mmol/L, whereas in the USA sevelamer carbonate is approved in adult CKD patients who require dialysis. Sevelamer carbonate and sevelamer hydrochloride achieved similar reductions in serum phosphate levels in randomized comparative trials in patients with CKD receiving haemodialysis; sevelamer carbonate also reduced serum phosphate levels in noncomparative studies in CKD patients not requiring dialysis. The most common adverse events with sevelamer carbonate are gastrointestinal in nature. Sevelamer has pleiotropic effects, such as improving the serum lipid profile and attenuating endothelial and cardiovascular risk factors in CKD. All formulations of sevelamer have markedly higher acquisition costs than calcium-based phosphate binders. Cost-effectiveness analyses focusing specifically on sevelamer carbonate have not been conducted, and those based on clinical trial data with sevelamer hydrochloride have provided both favourable and unfavourable results compared with calcium-based phosphate binders, reflecting heterogeneity between modelled analyses in terms of data sources, assumptions, comparators, geographical regions, type of costs included and other factors. Although well-designed studies evaluating the impact of phosphate binders on hard clinical endpoints appear to be warranted, sevelamer carbonate may be particularly useful for the treatment of patients at risk of metabolic acidosis (offering advantages over sevelamer hydrochloride in this regard) and for individuals requiring treatment with a phosphate binding agent that does not contain aluminium or calcium.

Citing Articles

A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials.

Zheng C, Liu J, Wang T, Hu H, Chen Y Sci Rep. 2025; 15(1):2012.

PMID: 39814766 PMC: 11736078. DOI: 10.1038/s41598-024-84942-8.


Efficacy and safety of sucroferric oxyhydroxide versus sevelamer carbonate: A systematic review and meta-analysis.

Georgopoulos C, Duni A, Stamellou E, Kitsos A, Gouva C, Dounousi E Hemodial Int. 2024; 29(1):6-16.

PMID: 39422162 PMC: 11730771. DOI: 10.1111/hdi.13187.


Histopathological lesions of the gastrointestinal tract associated with the use of polystyrene sulfonate and sevelamer: a meta-analysis.

Di Rienzo G, Crafa P, Delsante M, Fiaccadori E, Pedrazzi G, Campanini N Pathologica. 2024; 116(4):216-221.

PMID: 39377503 PMC: 11460155. DOI: 10.32074/1591-951X-994.


The deposition of lanthanum carbonate may activate macrophages to induce gastrointestinal mucosal injury in patients with chronic kidney disease: an in vitro caco-2/THP-1 macrophage coculture model study.

Song Y, Liu H, Yang X J Biol Inorg Chem. 2023; 29(1):101-112.

PMID: 38148422 DOI: 10.1007/s00775-023-02033-x.


Phosphate binders as a cause of hypothyroidism in dialysis patients: practical indications from a review of the literature.

Cataldo E, Columbano V, Nielsen L, Gendrot L, Covella B, Piccoli G BMC Nephrol. 2018; 19(1):155.

PMID: 29966512 PMC: 6027573. DOI: 10.1186/s12882-018-0947-9.


References
1.
Sun P, Perianayagam M, Jaber B . Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study. J Ren Nutr. 2009; 19(5):432-8. DOI: 10.1053/j.jrn.2009.01.022. View

2.
Iwata Y, Wada T, Yokoyama H, Toyama T, Kitajima S, Okumura T . Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels. Intern Med. 2007; 46(8):447-52. DOI: 10.2169/internalmedicine.46.6338. View

3.
Ishida M, Yao N, Yachiku S, Anzai T, Kobayashi T, Ishida H . Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy. Ther Apher Dial. 2005; 9 Suppl 1:S16-21. DOI: 10.1111/j.1744-9987.2005.00325.x. View

4.
Pai A, Shepler B . Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy. 2009; 29(5):554-61. DOI: 10.1592/phco.29.5.554. View

5.
Delmez J, Block G, Robertson J, Chasan-Taber S, Blair A, Dillon M . A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol. 2008; 68(6):386-91. DOI: 10.5414/cnp68386. View